All News
Pregnancy in SLE: Risks Extend Beyond Clinical Concerns
While clinical comorbidities such as lupus nephritis, hypertension, and thrombocytopenia have traditionally dominated risk assessments, new findings presented at EULAR 2025 spotlight the critical—and often underrecognized—role of social determinants of health (SDOH) in shaping maternal outcomes.
Read Article
Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases
During EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD). This is an anti-neonatal Fc receptor (FcRn) mAb that reduces circulating IgG, including autoantibodies, by selectively blocking the interaction of IgG with FcRn. A year on at EULAR 2025, data from Phase 2 RCT of efgartigimod, an FcRn-inhibitor were presented in autoantibodies positive, moderate to severe active SjD. In addition to SjD, data from Phase 2 RCT of efgartigimod in inflammatory myopathies was presented.
Read Article
Eular 2025 PsA Topic Panel
https://t.co/wJ08aKGZfJ https://t.co/6OvkIeOT76
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – SpA Panel Discussion
Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes.
https://t.co/AcwtseWBi0 https://t.co/MzEN0VtLx6
Dr. John Cush RheumNow ( View Tweet)
A new mechanism of action in SARD-ILD
Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases. FIBRONEER-ILD, the Phase 3 RCT of Nerandomilast in patients with progressive pulmonary fibrosis, was https://t.co/goikCwJa2x
Dr. John Cush RheumNow ( View Tweet)
Not All About B Cells: Myeloid Related Inflammation in Lupus Pathogenesis
Dr. Andrea Fava shares his perspectives from the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/8Lh02c3sy4 https://t.co/XX7wKovD9u
Dr. John Cush RheumNow ( View Tweet)
Secukinumab & Uveitis = Unclear? Post hoc study of 11 SEC RCTs finds lower uveitis risk in AxSpA (N 1980; SEC 150 1.29/100PYs vs 1.72/100PY in PBO), but not in PsA (N 2453; SEC 300 0.71/100PY vs zero w/ placebo) https://t.co/Gv9HheBU7l https://t.co/SlnrLRwmmn
Dr. John Cush RheumNow ( View Tweet)
Nurse-Led Treat-to-Target Clinics
New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems.
https://t.co/sV8IHhnwbm https://t.co/IrJKvceyez
Dr. John Cush RheumNow ( View Tweet)
#EULAR2025 TriNetX database study indicated that fibromyalgia patients who used glucagon-like peptide-1 (GLP-1) receptor agonist drugs were less likely to use opioids and to report pain, fatigue, and malaise compared with propensity-matched non-users https://t.co/ftm93VwW65 https://t.co/2wloutoX8a
Dr. John Cush RheumNow ( View Tweet)
Expanding the IL-17 Therapeutic Landscape
IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. https://t.co/Q7Thp1HJAL
Dr. John Cush RheumNow ( View Tweet)
The Value of Kidney Biopsy in Autoimmune Diseases
Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/CA6Ak2scKb https://t.co/EK5wdpbzrl
Dr. John Cush RheumNow ( View Tweet)
ALTO: Long-term Outcomes of APIPPRA
Dr. Mrinalini Dey interviews Professor Andrew Cope about abstract OP0004, on the long term outcome of APIPPRA patients - the ALTO study, at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/9wVZSXbi6r https://t.co/fm77qDoTwm
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – Day 4 Report
Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. https://t.co/ZJ1pHQJTbK
Dr. John Cush RheumNow ( View Tweet)
Lessons on Uveitis and AxSpA
Dr. Adela Castro reporting from the 2025 EULAR meeting in Barcelona
https://t.co/G0lDGDhpTh https://t.co/UWBSgTLyQm
Dr. John Cush RheumNow ( View Tweet)
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia
The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence (AI) and digital health technologies. Traditionally, treatment has centered around https://t.co/5CCpZqkm7K
Dr. John Cush RheumNow ( View Tweet)
Vector borne diseases that result in arthritis will rise with climate change/ flooding risk
- Chikungunya
- Dengue
- Zika
- West-Nile Virus
@RheumNow #EULAR2025 @bella_mehta https://t.co/CCOYqTjaXE
Dr. John Cush RheumNow ( View Tweet)
Reviewing Three Osteoarthritis Studies
Dr. Janet Pope discusses abstracts POS0492, abstract POS0565, and abstract POS0612 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/0qub4ITnxa https://t.co/uguzPSnvCR
Dr. John Cush RheumNow ( View Tweet)
Which CAR T Cell is Mighty?
Dr. Yuz Yusof talks with Dr. Chris Wincup about CAR T data being presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/MkRoqlvdub https://t.co/R0dtllmo7Q
Dr. John Cush RheumNow ( View Tweet)
Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory https://t.co/35cWYRehdd
Dr. John Cush RheumNow ( View Tweet)
EULAR Daily Recap: Day 1 and 2
LIVE Daily Recap Day 1 & 2 – EULAR 2025 Coverage brings you the latest updates from EULAR 2025. Join Dr. Jack Cush, Dr. Mrinalini Dey, Dr. Antoni Chan, and Dr. Nelly Ziade as they discuss the biggest breakthroughs, standout sessions, and expert https://t.co/vkTo2MchsC
Dr. John Cush RheumNow ( View Tweet)
